Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Non Operating Investment Income (2018 - 2025)

Lexaria Bioscience's Non Operating Investment Income history spans 8 years, with the latest figure at -$22093.0 for Q4 2025.

  • Quarterly results put Non Operating Investment Income at -$22093.0 for Q4 2025, down 38.67% from a year ago — trailing twelve months through Feb 2026 was -$73915.0 (down 436.2% YoY), and the annual figure for FY2025 was -$33714.0, up 51.72%.
  • Non Operating Investment Income for Q4 2025 was -$22093.0 at Lexaria Bioscience, down from -$11447.0 in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $34040.0 in Q1 2025 to a low of -$143918.0 in Q3 2023.
  • The 5-year median for Non Operating Investment Income is -$19012.5 (2024), against an average of -$27764.1.
  • The sharpest move saw Non Operating Investment Income tumbled 4307.73% in 2021, then soared 862.51% in 2024.
  • Year by year, Non Operating Investment Income stood at -$41362.0 in 2021, then crashed by 87.68% to -$77628.0 in 2022, then skyrocketed by 31.45% to -$53215.0 in 2023, then surged by 70.06% to -$15932.0 in 2024, then tumbled by 38.67% to -$22093.0 in 2025.
  • According to Business Quant data, Non Operating Investment Income over the past three periods came in at -$22093.0, -$11447.0, and -$40375.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.